Thomas Haughey - 21 May 2026 Form 4 Insider Report for ANI PHARMACEUTICALS INC (ANIP)

Reporting relationship: Director
Issuer ticker: ANIP
Reported as of: 21 May 2026
Net transaction value: -$161,760
SEC form: 4
Accepted by SEC: 10 Jun 2026, 21:06:55 UTC
Prior SEC filing: 14 Aug 2025
Source filing: View source filing
Reporting owner signature: /s/ Thomas Haughey, by attorney-in-fact Meredith W. Cook

Key filing fact

Thomas Haughey filed Form 4 for ANI PHARMACEUTICALS INC (ANIP) on 10 Jun 2026.

Key facts

This page summarizes Thomas Haughey's Form 4 filing for ANI PHARMACEUTICALS INC (ANIP).
2 reported transactions and 0 derivative rows are listed below.
Accepted by SEC: 10 Jun 2026, 21:06.

Change

Previous filing in this sequence was filed on 14 Aug 2025.
Current net transaction value: -$161,760.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001272247 Primary reporting owner

HAUGHEY THOMAS

Relationship: Director
Address: C/O ANI PHARMACEUTICALS, INC., 104 CARNEGIE CENTER, SUITE 300, PRINCETON
Signature: /s/ Thomas Haughey, by attorney-in-fact Meredith W. Cook
Signature date: 10 Jun 2026

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

ANIP transaction

Common Stock

Award

Transaction value
Shares: +4,357
Change %: +12%
Price: $0.000000^*
Shares after: 40,878
Date: 21 May 2026
Ownership: Direct
Footnotes: F1

ANIP transaction

Common Stock

Sale

Transaction value: $161,760
Shares: -2,000
Change %: -4.9%
Price: $80.88
Shares after: 38,878
Date: 08 Jun 2026
Ownership: Direct
Footnotes: F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Rule 10b5-1 trading plan

These transactions were reported as open-market trades under a Rule 10b5-1 plan. The plan lets an insider set trading instructions in advance, which can reduce the risk of trading while in possession of material nonpublic information.

Original filing language: transaction made pursuant to a contract, instruction, or written plan intended to satisfy Rule 10b5-1(c).

Explanation of responses 2 footnotes

Footnote F1

Represents a restricted stock award that will vest in full on May 21, 2027.

Footnote F2

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 9, 2026.